Literature DB >> 22228785

Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas.

Haruki Koike1, Fumiaki Tanaka, Rina Hashimoto, Minoru Tomita, Yuichi Kawagashira, Masahiro Iijima, Junko Fujitake, Toru Kawanami, Takeo Kato, Masahiko Yamamoto, Gen Sobue.   

Abstract

OBJECTIVE: The objective of this study was to elucidate the natural history of late-onset transthyretin Val30Met-associated familial amyloid polyneuropathy (FAP ATTR Val30Met) in non-endemic areas.
METHODS: The authors retrospectively assessed the development of major clinical landmarks and abnormalities of nerve conduction and cardiac examination indices in 50 patients with an age of onset older than 50 years and no relationship to endemic foci.
RESULTS: Once the neuropathic process was initiated, sensory and motor symptoms of both the upper and lower extremities appeared within a period of one and a half years. Digestive and orthostatic symptoms also tended to occur in the early phase of the disease, whereas urinary symptoms appeared in the middle of the disease progress. Along with pain in the extremities, these symptoms progressed over time and significantly disturbed the quality of life during the late phase of the disease, resulting in the need for wheelchair use. Although cardiomyopathy became clinically apparent only in the late phase of the disease, it was found to be the major cause of death. The mean duration of the disease onset to death was 7.3 years. Although values at the time of diagnosis were extremely variable, serial measurements of electrophysiological indices, the cardiothoracic ratio and interventricular septum thickness indicated a steady exacerbation in these outcomes among patients within a span of a couple of years.
CONCLUSIONS: The ages of onset of each clinical landmark were extremely variable between patients. However, once an initial symptom appeared, the chronological sequence of other clinical landmarks tended to be uniform, occurring within a relatively short time span.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228785     DOI: 10.1136/jnnp-2011-301299

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  58 in total

Review 1.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

Review 2.  [Hereditary transthyretin amyloidosis].

Authors:  E Hund
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

3.  Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.

Authors:  A Cortese; G Vita; M Luigetti; M Russo; G Bisogni; M Sabatelli; F Manganelli; L Santoro; T Cavallaro; G M Fabrizi; A Schenone; M Grandis; C Gemelli; A Mauro; L G Pradotto; L Gentile; C Stancanelli; A Lozza; S Perlini; G Piscosquito; D Calabrese; A Mazzeo; L Obici; D Pareyson
Journal:  J Neurol       Date:  2016-03-16       Impact factor: 4.849

Review 4.  FAP neuropathy and emerging treatments.

Authors:  David Adams; Marie Théaudin; Cecile Cauquil; Vincent Algalarrondo; Michel Slama
Journal:  Curr Neurol Neurosci Rep       Date:  2014-03       Impact factor: 5.081

5.  Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study.

Authors:  David Adams; Teresa Coelho; Laura Obici; Giampaolo Merlini; Zoia Mincheva; Narupat Suanprasert; Brian R Bettencourt; Jared A Gollob; Pritesh J Gandhi; William J Litchy; Peter J Dyck
Journal:  Neurology       Date:  2015-07-24       Impact factor: 9.910

6.  Recent advances in the treatment of familial amyloid polyneuropathy.

Authors:  David Adams
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

7.  Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox?

Authors:  Adam J Loavenbruck; Wolfgang Singer; Michelle L Mauermann; Paola Sandroni; P James B Dyck; Morie Gertz; Christopher J Klein; Phillip A Low
Journal:  Ann Neurol       Date:  2016-07-25       Impact factor: 10.422

8.  Life paths of patients with transthyretin-related familial amyloid polyneuropathy Val30Met: a descriptive study.

Authors:  Alice Lopes; Alexandra Sousa; Isabel Fonseca; Margarida Branco; Carla Rodrigues; Teresa Coelho; Jorge Sequeiros; Paula Freitas
Journal:  J Community Genet       Date:  2017-10-19

9.  Cardiac and peripheral vasomotor autonomic functions in late-onset transthyretin Val30Met familial amyloid polyneuropathy.

Authors:  Haruki Koike; Tomohiko Nakamura; Atsushi Hashizume; Ryoji Nishi; Shohei Ikeda; Yuichi Kawagashira; Masahiro Iijima; Masahisa Katsuno; Gen Sobue
Journal:  J Neurol       Date:  2017-10-05       Impact factor: 4.849

10.  Carpal tunnel syndrome and associated symptoms as first manifestation of hATTR amyloidosis.

Authors:  Chafic Karam; Diana Dimitrova; Megan Christ; Stephen B Heitner
Journal:  Neurol Clin Pract       Date:  2019-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.